Galapagos to Present Promising CAR-T Study Data at EHA and ICML 2025

An update from Galapagos ( (GLPG) ) is now available.

On May 14, 2025, Galapagos announced that new data from their ATALANTA-1 Phase 1/2 study of the investigational CAR-T candidate GLPG5101 for relapsed/refractory non-Hodgkin lymphoma will be presented at upcoming conferences. The presentations at the European Hematology Association Congress and the International Conference on Malignant Lymphoma will highlight safety, efficacy, and translational data, supporting the potential of GLPG5101 to improve patient outcomes. This development underscores Galapagos’ commitment to advancing cell therapies for serious hematological conditions and enhancing their industry positioning.

The most recent analyst rating on (GLPG) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.

Spark’s Take on GLPG Stock

According to Spark, TipRanks’ AI Analyst, GLPG is a Neutral.

Galapagos’s overall stock score is driven by its financial stability and strong cash reserves, offset by significant profitability and cash flow challenges. Technical indicators show a mildly positive trend, while valuation remains unattractive due to negative earnings. The earnings call highlights strategic initiatives and a robust pipeline, but high restructuring costs and expected cash burn are notable risks.

To see Spark’s full report on GLPG stock, click here.

More about Galapagos

Galapagos is a biotechnology company with operations in Europe, the U.S., and Asia, focused on transforming patient outcomes through innovative science. The company addresses high unmet medical needs by developing a deep pipeline of best-in-class medicines, including a decentralized cell therapy manufacturing platform.

Average Trading Volume: 338,352

Technical Sentiment Signal: Strong Sell

Current Market Cap: $1.68B

For an in-depth examination of GLPG stock, go to TipRanks’ Stock Analysis page.